COMPETE dosimetry poster lands at SNMMI 2026

ITM Isotope Technologies Munich will present dosimetry data from its phase 3 COMPETE trial at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Los Angeles. The poster will be displayed from May 31 to June 2 at the SNMMI Science Pavilion, according to the company.

The poster is titled “Accurate single-time-point dosimetry of [177Lu]Lu-edotreotide using non-linear mixed-effects modeling: results from the COMPETE Phase 3 trial.” ITM said the presentation will cover dosimetry of Lu-177 edotreotide, also known as ITM-11.

COMPETE evaluated Lu-177 edotreotide against everolimus in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors. ITM said the study met its primary endpoint, with Lu-177 edotreotide showing a clinically and statistically significant improvement in progression-free survival compared with everolimus.

The phase 3 trial enrolled 309 patients across Europe, the U.S., Australia, and South Africa. Patients were randomized 2:1 to receive either Lu-177 edotreotide every 3 months for up to 4 cycles or everolimus 10 mg daily for up to 30 months, according to ITM’s COMPETE trial page.

Median progression-free survival was 23.9 months with Lu-177 edotreotide compared with 14.1 months with everolimus, with a p value of 0.022 and hazard ratio of 0.67. ITM also reported interim median overall survival of 63.4 months with Lu-177 edotreotide and 58.7 months with everolimus, though the overall survival analysis was not statistically significant.

Dosimetry was used in COMPETE to assess absorbed dose in tumors compared with healthy tissue. ITM said the method was used to support safety and efficacy monitoring of the investigational therapy.

The company will also host a May 31 satellite symposium on somatostatin receptor-targeted radiopharmaceutical therapy. The session will discuss earlier approaches, current Lu-177 agonist therapies, next-generation ligand biology, and emerging radionuclides.

Lu-177 edotreotide remains investigational. FDA accepted ITM’s new drug application in November 2025 and set a Prescription Drug User Fee Act goal date of August 28, 2026.